Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings

7 Oct 2014

Abstract excerpt

BACKGROUND: To guide future need for cheap resistance tests for use in low income settings, we assessed cost-effectiveness of drug resistance testing as part of monitoring of people on first line ART - with switching from first to second line ART being conditional on NNRTI drug resistance mutations being identified. METHODS: An individual level simulation model of HIV transmission, progression and the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Research and Disease Studies
Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25290340
DOI: 10.1371/journal.pone.0109148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income SettingsPMID 25290340Read ↗

Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan womenSemantic proximity Read ↗

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Semantic proximity Read ↗

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.Semantic proximity Read ↗

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Semantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.Semantic proximity Read ↗

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisSemantic proximity Read ↗

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.Semantic proximity Read ↗

The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV-Infected PatientsSemantic proximity Read ↗

The cost of antiretroviral drug resistance in HIV-positive patients.Semantic proximity Read ↗

Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settingsSemantic proximity Read ↗

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.